These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21847689)

  • 21. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.
    Schank JR; Goldstein AL; Rowe KE; King CE; Marusich JA; Wiley JL; Carroll FI; Thorsell A; Heilig M
    Addict Biol; 2012 May; 17(3):634-47. PubMed ID: 22515275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats.
    Silva RM; Grossman HC; Hadjimarkou MM; Rossi GC; Pasternak GW; Bodnar RJ
    J Pharmacol Exp Ther; 2002 May; 301(2):513-8. PubMed ID: 11961051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging.
    Zheng MQ; Nabulsi N; Kim SJ; Tomasi G; Lin SF; Mitch C; Quimby S; Barth V; Rash K; Masters J; Navarro A; Seest E; Morris ED; Carson RE; Huang Y
    J Nucl Med; 2013 Mar; 54(3):455-63. PubMed ID: 23353688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.
    Zheng Z; Huang XP; Mangano TJ; Zou R; Chen X; Zaidi SA; Roth BL; Stevens RC; Katritch V
    J Med Chem; 2017 Apr; 60(7):3070-3081. PubMed ID: 28339199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kappa opioid agonist-induced changes in IOP: correlation with 3H-NE release and cAMP accumulation.
    Moore TT; Potter DE
    Exp Eye Res; 2001 Aug; 73(2):167-78. PubMed ID: 11446767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats.
    Briggs SL; Rech RH; Sawyer DC
    Pharmacol Biochem Behav; 1998 Jun; 60(2):467-72. PubMed ID: 9632230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.
    Rorick-Kehn LM; Witcher JW; Lowe SL; Gonzales CR; Weller MA; Bell RL; Hart JC; Need AB; McKinzie JH; Statnick MA; Suico JG; McKinzie DL; Tauscher-Wisniewski S; Mitch CH; Stoltz RR; Wong CJ
    Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25637376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maturational alterations in constitutive activity of medial prefrontal cortex kappa-opioid receptors in Wistar rats.
    Sirohi S; Walker BM
    J Neurochem; 2015 Nov; 135(4):659-65. PubMed ID: 26257334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
    Olianas MC; Concas D; Onali P
    Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonism of the discriminative stimulus effects of the kappa-opioid agonist spiradoline.
    Holtzman SG; Steinfels GF
    Psychopharmacology (Berl); 1994 Nov; 116(3):243-8. PubMed ID: 7892412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders.
    Jacobson ML; Browne CA; Lucki I
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():615-636. PubMed ID: 31914893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist.
    Li CS; Zhang L; Haske T; Dounay A; Gray D; Barta N; Brodfuehrer J; Lepsy C; Campbell B
    AAPS J; 2012 Jun; 14(2):365-76. PubMed ID: 22454087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
    Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.
    Townsend EA
    Psychopharmacology (Berl); 2021 Apr; 238(4):1017-1028. PubMed ID: 33404739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
    Jackson KJ; Jackson A; Carroll FI; Damaj MI
    Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid receptor subtypes involved in the regulation of prolactin secretion during pregnancy and lactation.
    Andrews ZB; Grattan DR
    J Neuroendocrinol; 2003 Mar; 15(3):227-36. PubMed ID: 12588510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
    Steinmiller CL; Young AM
    Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Participation of dorsal periaqueductal gray 5-HT1A receptors in the panicolytic-like effect of the κ-opioid receptor antagonist Nor-BNI.
    Maraschin JC; Almeida CB; Rangel MP; Roncon CM; Sestile CC; Zangrossi H; Graeff FG; Audi EA
    Behav Brain Res; 2017 Jun; 327():75-82. PubMed ID: 28347824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.